Giorgia Zadra, Ph.D.
Ph.D. in Molecular Oncology at University of Milan Italy, 2007
Giorgia is investigating three closely related areas of research. First, the potential of a target therapy approach versus a fundamental metabolic regulator like 5' AMP-activated protein kinase in Prostate Cancer (PCa) using in vitro, fresh human tumor tissue slices, and in vivo models. Second, the complex regulation between AMPK and the metabolic enzyme Fatty Acid Synthase in PCa, using computational approaches and in vitro validation experiments. And third, regulation of PCa metabolism through miRNAs using PCa cell lines and human tumors.
Senior Research Technician
Sudeepa is a Senior Research assistant. She is currently involved in projects looking at the effect of high fat diet on prostate cancer and testing new small molecules aimed at inhibiting de novo lipogenesis in using in vitro, xenograft, and GEMM models of prostate cancer.
Habiba Elfandy, M.D.
Research pathologist; PhD candidate, Cairo University
Habiba is investigating and validating prostate cancer molecular fingerprint derived from integrative genomics (SCNV, mutation and gene-expression) linked with certain histomorphologic patterns and their relation to the tumor lethality. Her focus is to describe the key molecular events that may further stratify men into different risk groups under certain histomorphologic patterns and explore their possible therapeutic and prognostic application. She is also contributing specialist expertise to underpin the quality of the ongoing research projects, both in human samples and mice models of prostate disease, for tissues provided from both frozen and FFPEs sources. Her support consists of providing pathology-based specific annotations, interpreting IHC, validating the appropriateness of the tissue samples and providing input on selection of best sections/tumor areas in terms of tumor grade, tissue viability & cellular density prior to the molecular testing and construction of TMAs, ect.
Paolo is a pathology resident from Milan with a special interest in molecular research on cancer.
Caroline is a biochemical engineer who studies the effect of de novo lipogenesis inhibition in prostate cancer cell lines, focusing in intracellular alterations involved with the androgen receptor signaling pathway